Honey has an antifungal effect against Candida species

Medical Mycology May 2006, 44, 289 /291

Short Communication

Honey has an antifungal effect against Candida species

Med Mycol Downloaded from informahealthcare.com by University of Sydney on 10/14/10 For personal use only.

JULIE IRISH*, DEE A. CARTER*, TAHEREH SHOKOHI$ & SHONA E. BLAIR* *School of Molecular and Microbial Biosciences, University of Sydney, New South Wales, Australia, and $Department of Medical Mycology and Parasitology, Mazandaran University of Medical Sciences, Sari, Iran

The incidence of Candida infections is escalating worldwide. The serious nature of these infections is compounded by increasing levels of drug resistance. We report that certain honeys have significant antifungal activity against clinical isolates of Candida species. Importantly, the minimum inhibitory concentration of these honeys would be achievable in a clinical setting. Keywords

honey, Candida, antifungal effect

Introduction Honey has been used as a medicine for thousands of years, and has been found to be an effective antimicrobial agent [1]. This antimicrobial activity stems primarily from the production of hydrogen peroxide from glucose and oxygen by glucose oxidase, a beederived enzyme [2]. Honey from certain species of Leptospermum flora native to Australia and New Zealand contains additional phytochemical components that further enhance its antibacterial activity [3]. The precise nature of these components is yet to be identified. Although several in vitro studies have demonstrated the antibacterial properties of honey [3 /5], few have examined the action against fungi. The incidence of fungal infections is increasing in both the community and hospital environments, with Candida spp. among the leading organisms. Candida albicans causes oral infections, over 50% of candidaemia cases [6 /9] and more than 90% of vaginal candidiasis [10,11]. Recently there have been increased reports of non-C. albicans Candida species in clinical studies. Candida glabrata has become the dominant non-C. albicans Candida species involved in bloodstream and vaginal infections [9,12/14], while Candida dubliniensis is often implicated in oropharyngeal candidiasis [15]. Infection

Received 8 August 2005; Accepted 17 October 2005 Correspondence: Julie Irish, School of Molecular and Microbial Biosciences, Building G08, University of Sydney, New South Wales, 2006, Australia. Tel: /61 2 9351 6041; Fax: /61 2 9351 4571; E-mail: [email protected]

– 2006 ISHAM

with non-C. albicans Candida species has important clinical implications, as many are resistant to conventional triazole-based antifungal therapy. Other conventional antifungal therapies are either toxic or of limited efficacy, and there is a growing need for new potent antifungal agents. The aim of the current study was to determine the efficacy of various honeys against clinical isolates of C. albicans, C. glabrata and C. dubliniensis.

Materials and methods Clinical isolates of C. albicans, C. glabrata and C. dubliniensis were tested against four different honeys: an unprocessed Jarrah honey with hydrogen peroxide activity (total antibacterial activity (as described in [16]) equivalent to 30.2% phenol [17]); Medihoney† Antibacterial Honey Barrier, a proprietary blend of Leptospermum and hydrogen peroxide honeys (phytochemical activity ]/18% phenol equivalent); Comvita† Wound Care 18/, a pure Leptospermum honey (phytochemical activity ]/18% phenol equivalent); and an artificial honey, used to simulate the high sugar levels found in honey (7.5 g sucrose, 37.5 g maltose, 167.5 g glucose, and 202.5 g fructose in 85 ml of sterile water). The minimum inhibitory concentration (MIC) of each honey was determined based on the NCCLS microdilution method [18]. Fifty percent (w/v) stock solutions of honey in RPMI-1640 medium (with glutamine and without bicarbonate (Sigma)) were prepared immediately before each assay and filter sterilised through 0.2 mm pore filters (Millipore). Stock solutions were further diluted with RPMI-1640 DOI: 10.1080/13693780500417037


290

Irish et al.

medium in 96-well microtitre plates to give final honey concentrations that increased in 1% (w/v) increments. Suspensions of Candida isolates were prepared in sterile 0.85% saline and transmittance at 530 nm was adjusted to 80/88%. Suspensions were diluted in RPMI-1640 medium, and 25 ml was added to each well of the microtitre plate immediately after preparation of the honey solutions, resulting in a final inoculum of 0.5 /2.5 /103 cfu/ml. Following incubation at 35oC for 24 h, the MIC was recorded as the lowest concentration of honey that prevented visible growth. Each Candida isolate was tested in duplicate and the assays were repeated on a separate day. The Mann-Whitney U test was used to evaluate statistically significant groups. Correlations were performed using the Spearman rank-order test.

Results Results of the susceptibility of C. albicans, C. glabrata , and C. dubliniensis to various honeys are shown in Table 1. Jarrah honey was significantly more active against the three Candida species (P B/ 0.00001). The antifungal activities of the floral honeys were significantly greater than the artificial honey against C. albicans and C. glabrata (P B/ 0.002), but for C. dubliniensis, only Jarrah honey was significantly more active (P B/ 0.00001). C. dubliniensis was more susceptible to the osmotic effect of all honeys, and to the antifungal effects of Jarrah honey, exhibiting significantly lower MICs than the other species (P B/ 0.00001). C. glabrata , which is innately less susceptible to many conventional antifungals [19], was the least susceptible to the honeys tested (P B/ 0.00001). Drug resistance profiles were available for 20 of the isolates. Twelve of these were either resistant or Table 1 Susceptibility of Candida species to different honey typesa Candida species (n )

Jarrah Medihoney† Antibacterial Honey Barrier Comvita† Wound Care 18/ Artificial honey a

C. albicans (18)

C. glabrata (10)

C. dubliniensis (10)

18.59/2.7** 38.29/2.9**

29.99/2.8** 43.19/4.2*

15.49/2.8** 34.69/2.5

39.99/1.7**

42.69/2.8**

33.49/2.5

42.69/1.8

44.79/2.7

34.39/2.4

Values show mean minimum inhibitory concentration (% (w/v) honey)9/standard deviation. *PB/ 0.002; **PB/ 0.00001. P values assessed in comparison to artificial honey.

susceptible-dose dependent to itraconazole and/or fluconazole. All of these isolates were inhibited by honey, with no statistical relationship between antifungal susceptibility and sensitivity to honey (P / 0.05).

Discussion Limited observations have found honey to have an inhibitory effect against C. albicans in vitro [20 /22], however none of these studies used standardized honeys or assay methods. Only one published study has used honey with known phenol-equivalent activity to examine antifungal activity [23]. In this study the effects of pasture honey were compared with Leptospermum honey against dermatophyte fungi. In accordance with the results of the current study the hydrogen peroxide-type honey was found to have a greater antifungal effect. The current study found no statistical relationship between antifungal susceptibility and sensitivity to honey. This is of particular importance considering the increasing rate of resistance to azole drugs among Candida isolates [8,24,25], and the finding that azolebased prophylaxis increases the risk of infection with non-C. albicans Candida species, which may be less responsive to usual drug dosages [6,24]. Although this study demonstrates the antifungal effect of honey in vitro there are some practical considerations for its use in vivo. Firstly, honey is limited to topical treatments, and could not be used to treat candidaemia, the most serious form of candidiasis. However, as the leading risk factor for bloodstream infection is colonization or infection of external sites, such as indwelling catheters, or the oral or vaginal mucosae [19], honey may be used prophylactically to prevent more serious infections. Whole honey placed directly around catheters was found to be at least as effective as povidone iodine [26] or mupirocin [27] in preventing exit site infection. Secondly, as honey is water soluble, it may be diluted or removed by body fluids, particularly saliva in the oral cavity. A pilot study by English et al . [28] found a significant reduction in mean plaque scores and bleeding sites in patients given a chewable ‘honey leather’; this same technique could be applied for the treatment of oral candidiasis. At other body sites, regular application of 100% honey would maintain a concentration well above the desired MIC. Honey could also be incorporated into a pessary for the treatment of vaginal candidiasis. Another practical issue is the presence of catalase in body fluids that has the potential to reduce hydrogen peroxide activity. However, case reports and clinical trials suggest sufficient activity is retained to – 2006 ISHAM, Medical Mycology, 44, 289 /291

Antifungal effects of honey against Candida

allow honey to be effective in the clinical setting [29,30]. The results of the current study argue for controlled clinical trials to establish honey as a topical antifungal agent.

12

13


Acknowledgements This work was supported by the Rural Industries Research and Development Corporation Honeybee Committee grant number US-128. Clinical isolates were kindly provided by Westmead Hospital Institute of Clinical Pathology and Medical Research, Sydney, Australia; and Mazandaran University of Medical Sciences, Sari, Iran. Honey samples were kindly provided by Medihoney Pty. Ltd., Queensland, Australia; Comvita Medical Ltd., Te Puke, New Zealand; and the Western Australian Beekeepers Association.

References 1 Zumla A, Lulat A. Honey / a remedy rediscovered. J R Soc Med 1989; 82: 384 /385. 2 White JW, Subers MH, Schepartz AI. The identification of inhibine, the antibacterial factor in honey, as hydrogen peroxide and its origin in a honey glucose-oxidase system. Biochim Biophys Acta 1963; 73: 57 /70. 3 Molan PC. The antibacterial activity of honey. 1. The nature of the antibacterial activity. Bee World 1992; 73: 5 /28. 4 Cooper RA, Molan PC, Harding KG. The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds. J Appl Microbiol 2002; 93: 857 /863. 5 Cooper RA, Molan PC. The use of honey as an antiseptic in managing Pseudomonas infection. J Wound Care 1999; 8: 161 / 164. 6 Abi-Said D, Anaissie E, Uzun O, et al . The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infec Dis 1997; 24: 1122 /1128. 7 Pfaller MA, Diekema DJ, Jones RN, et al . International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254 /3259. 8 Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans : frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998; 31: 327 /332. 9 Tortorano AM, Peman J, Bernhardt H, et al . Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317 /322. 10 Sobel JD, Zervos M, Reed BD, et al . Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34 /38. 11 Sobel JD, Kapernick PS, Zervos M, et al . Treatment of complicated Candida vaginitis: comparison of single and

– 2006 ISHAM, Medical Mycology, 44, 289 /291

14

15

16

17 18

19

20

21 22

23

24

25

26 27

28

29 30

291

sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185: 363 /369. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569 /574. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidaemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551 /3557. Sobel JD, Faro S, Force RW, et al . Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203 /211. Sullivan DJ, Moran GP, Pinjon E, et al . Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 2004; 4: 369 /376. Allen KL, Molan PC, Reid GM. A survey of the antibacterial activity of some New Zealand honeys. J Pharm Pharmacol 1991; 43: 817 /822. Manning R. Antibacterial activity (hydrogen peroxide) of some Western Australian honeys. (manuscript in preparation) 2005. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard , M27-A2, 2nd edn. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infec Dis 2003; 3: 685 /702. Theunissen F, Grobler S, Gedalia I. The antifungal action of three South African honeys on Candida albicans. Apidologie 2001; 32: 371 /379. Efem SE, Udoh KT, Iwara CI. The antimicrobial spectrum of honey and its clinical significance. Infection 1992; 20: 227 /229. Adeleye IA, Opiah L. Antimicrobial activity of extracts of local cough mixtures on upper respiratory tract bacterial pathogens. West Indian Med J 2003; 52: 188 /190. Brady NF, Molan PC, Harfoot CG. The sensitivity of dermatophytes to the antimicrobial activity of manuka honey and other honey. Pharm Sci 1996; 2: 471 /473. Nguyen MH, Peacock JE, Morris AJ, et al . The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617 /623. Wroblewska MM, Swoboda-Kopec E, Rokosz A, et al . Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles. Int J Antimicrob Agents 2002; 20: 472 /475. Quadri KH, Huraib SO. Manuka honey for central vein catheter exit site care. Dialysis Clinic 1999: 397 /398. Johnson DW, van Eps C, Mudge DW, et al . Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J Am Soc Nephrol 2005; 16: 1456 /1462. English HK, Pack AR, Molan PC. The effects of manuka honey on plaque and gingivitis: a pilot study. J Int Acad Periodontol 2004; 6: 63 /67. Efem SEE. Clinical observations on the wound healing properties of honey. Br J Surg 1988; 75: 679 /681. Molan PC, Betts JA. Clinical usage of honey as a wound dressing: an update. J Wound Care 2004; 13: 353 /356.